The expression of GBP1 is under control of IFN-γ [43,44] and blocking of the IFN-γ pathway with inhibitor doses ≥5 μg/ml significantly decreased GBP1 expression (Fig. 5c and d) and significantly decreased passage of breast cancer cells through our in vitro BBB model (Fig. 5a). The gene discussed is GBP1; the disease is breast carcinoma.